Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Urges Development Of 91 Drugs; Seeks Public Recruitment For 17 To Ease Drug Lag

This article was originally published in PharmAsia News

Executive Summary

TOKYO - The Ministry of Health, Labor and Welfare has asked pharmaceutical manufacturers that have licenses to proactively develop 91 products in Japan that are not currently approved for use in Japan, ministry officials said June 2. Of the total, the ministry began publicly recruiting developers for 19 drugs

You may also be interested in...



Japanese Health Ministry To Ask Drug Makers To Submit Applications For 100-plus Pharmaceutical Products; Vows Quick Review Process

TOKYO - In an unusual move aimed at solving part of Japan's drug lag problem, the Ministry of Health, Labor and Welfare is set to ask pharmaceutical makers to submit applications to market a total of 109 drugs that have already been approved in other countries, an MHLW official said May 10

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel